185 related articles for article (PubMed ID: 25422223)
1. Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.
Zhou JY; He LW; Liu J; Yu HL; Wei M; Ma WL; Shi R
Asian Pac J Cancer Prev; 2014; 15(21):9347-53. PubMed ID: 25422223
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
Ma Q; Qi C; Tie C; Guo Z
Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
[TBL] [Abstract][Full Text] [Related]
3. Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin's lymphoma: evidence from a meta-analysis.
Chen S; Zhu JH; Wang F; Huang SY; Xue WQ; Cui Z; He J; Jia WH
Chin J Cancer; 2015 Mar; 34(3):108-14. PubMed ID: 25962431
[TBL] [Abstract][Full Text] [Related]
4. Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis.
Peng Q; Li S; Lao X; Chen Z; Li R; Qin X
Medicine (Baltimore); 2014 Dec; 93(29):e330. PubMed ID: 25546681
[TBL] [Abstract][Full Text] [Related]
5. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
[TBL] [Abstract][Full Text] [Related]
6. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
[TBL] [Abstract][Full Text] [Related]
7. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.
Xue H; Lu Y; Lin B; Chen J; Tang F; Huang G
PLoS One; 2012; 7(9):e43431. PubMed ID: 23028453
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer.
Pabalan N; Francisco-Pabalan O; Sung L; Jarjanazi H; Ozcelik H
Breast Cancer Res Treat; 2010 Nov; 124(2):531-41. PubMed ID: 20379847
[TBL] [Abstract][Full Text] [Related]
9. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
[TBL] [Abstract][Full Text] [Related]
10. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.
Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H
Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498
[TBL] [Abstract][Full Text] [Related]
11. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
Zhou X; Zeng Y; Jiang H; Xia L; Liu C
Melanoma Res; 2018 Aug; 28(4):311-318. PubMed ID: 29768284
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of xeroderma pigmentosum group D and prostate cancer risk: a meta-analysis.
Zhu H; Cao S; Liu Y; Ding X; Wu Q; Ma H
J Cancer Res Ther; 2013; 9(2):187-92. PubMed ID: 23771356
[TBL] [Abstract][Full Text] [Related]
14. A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPD Lys751Gln but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population.
Yin J; Vogel U; Ma Y; Qi R; Sun Z; Wang H
Cancer Genet Cytogenet; 2007 May; 175(1):47-51. PubMed ID: 17498557
[TBL] [Abstract][Full Text] [Related]
15. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies.
Zhan P; Wang Q; Wei SZ; Wang J; Qian Q; Yu LK; Song Y
J Thorac Oncol; 2010 Sep; 5(9):1337-45. PubMed ID: 20651612
[TBL] [Abstract][Full Text] [Related]
16. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.
Ding DP; Ma WL; He XF; Zhang Y
Mol Biol Rep; 2012 Mar; 39(3):2533-40. PubMed ID: 21667112
[TBL] [Abstract][Full Text] [Related]
17. ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis.
Chen B; Zhou Y; Yang P; Wu XT
J Cancer Res Clin Oncol; 2011 Jun; 137(6):939-46. PubMed ID: 20981556
[TBL] [Abstract][Full Text] [Related]
18. XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis.
Cui J; Li D; Shen L; Zhang W; Xu X
Tumour Biol; 2014 Jul; 35(7):6335-41. PubMed ID: 24652592
[TBL] [Abstract][Full Text] [Related]
19. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
[TBL] [Abstract][Full Text] [Related]
20. Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.
Xiao F; Pu J; Wen Q; Huang Q; Zhang Q; Huang B; Huang S; Lan A; Zhang Y; Li J; Zhao D; Shen J; Wu H; He Y; Li H; Yang X
Oncotarget; 2017 Jul; 8(29):48488-48506. PubMed ID: 28489582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
